GlassScriptPhysician profile
Bhudev Sharma
NPI 1477555100
$16,166.13
in general payments reported to CMS, 2019-2025
44 companies · $2,186 in 2025
The $2,186 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,182 · 2020: $1,382 · 2021: $3,359 · 2022: $2,912 · 2023: $1,934 · 2024: $3,211 · 2025: $2,186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,330.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,573.42 | 2019-2025 | Farxiga, Lokelma, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,448.74 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $1,314.89 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,186.36 | 2019-2024 | Xarelto |
| Abbott Laboratories | $1,126.46 | 2019-2025 | Amplatzer Amulet, Aveir, Mitraclip |
| Biotronik INC. | $1,118.14 | 2019-2025 | Biomonitor, Amvia Edge, Acticor 7 Vr-T Dx |
| E.R. Squibb & Sons, L.L.C. | $754.89 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $719.69 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $696.13 | 2019-2024 | Watchman, Watchman Access System, Watchman Flx |
| Novo Nordisk INC | $677.29 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $569.04 | 2019-2024 | |
| Glaxosmithkline, LLC. | $529.29 | 2021-2025 | Arexvy, Shingrix |
| Vital Connect, INC | $460.63 | 2024-2025 | Vitalpatch Rtm |
| Cvrx, INC. | $449.93 | 2023-2025 | Barostim Neo System |
| Pfizer INC. | $441.35 | 2019-2025 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $284.32 | 2022-2025 | Linq II |
| Merck Sharp & Dohme LLC | $278.55 | 2020-2024 | Verquvo |
| Viiv Healthcare Company | $249.86 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $227.19 | 2023-2024 | Inpefa |
| Kowa Pharmaceuticals America, INC. | $212.55 | 2020-2022 | |
| Amarin Pharma, INC. | $180.90 | 2019-2021 | |
| Impulse Dynamics (USA) INC. | $155.83 | 2021-2024 | Optimizer |
| Daiichi Sankyo INC. | $148.96 | 2021-2024 | Injectafer |
| Edwards Lifesciences Corporation | $137.69 | 2020-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Insmed, INC. | $133.28 | 2023 | Arikayce |
| Phathom Pharmaceuticals, INC. | $121.33 | 2025 | Voquezna |
| Scpharmaceuticals INC. | $120.62 | 2024 | |
| Zoll Respicardia, INC. | $118.71 | 2023 | Remede System |
| Lilly USA, LLC | $99.20 | 2020 | |
| Gilead Sciences, INC. | $98.58 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.33 | 2021-2025 | |
| Heartflow, INC. | $88.12 | 2024-2025 | |
| Abiomed | $82.86 | 2024-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $46.27 | 2022-2023 | Lifevest |
| Astellas Pharma US INC | $40.73 | 2019-2021 | |
| Baxter Healthcare | $32.61 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Esperion Therapeutics, INC. | $26.13 | 2021 | |
| Exact Sciences Corporation | $23.68 | 2024 | Cologuard Collection Kit |
| Atricure, INC. | $22.62 | 2025 | Atriclip Laa Exclusion System |
| Validus Pharmaceuticals LLC | $17.89 | 2025 | Raldesy |
| Bridgebio Pharma, INC. | $15.88 | 2025 | Attruby |
| Arbor Pharmaceuticals, INC. | $15.22 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $14.98 | 2024 | Arcalyst |
| Althera Pharmaceuticals LLC | $13.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhudev Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.